Histone lysine methyltransferases as anti-cancer targets for drug discovery
- 11 July 2016
- journal article
- review article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 37 (10) , 1273-1280
Abstract
APS (Acta Pharmacologica Sinica), the top pharmacology research journal based in China, publishes original articles and reviews on all aspects of pharmacology and the related life sciencesKeywords
This publication has 57 references indexed in Scilit:
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)Proceedings of the National Academy of Sciences, 2012
- Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic StudiesJournal of the American Chemical Society, 2011
- Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolinesJournal of Medicinal Chemistry, 2011
- A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cellsNature Chemical Biology, 2011
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center originNature Genetics, 2010
- Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294Nature Structural & Molecular Biology, 2009
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different MechanismsMolecular Cell, 2008
- Chemical probes for histone-modifying enzymesNature Chemical Biology, 2008
- The Epigenomics of CancerCell, 2007
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004